智通财经APP获悉,因塞特(INCY.US)已经终止了与Syros Pharmaceuticals(SYRS.US)在骨髓增生性肿瘤治疗方面的发现和研究合作。终止协议将在8月9日起60天内生效。 2018年1月,因塞特和Syros Pharmaceuticals首次签署了一项合作协议。作为合... 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080480 Size: 4 KB 网页链接
$Syros(SYRS)$ 144 Report of proposed sale of securities Accession Number: 0001973141-24-000326 Act: 33 Size: 4 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070708 Size: 7 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070701 Size: 7 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070703 Size: 6 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070713 Size: 6 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070711 Size: 6 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070714 Size: 6 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070704 Size: 8 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070706 Size: 6 KB 网页链接